Contemporary and Emerging Approaches to Bladder-Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer.

Bladder-preserving trimodality therapy (TMT), consisting of trans-urethral bladder tumor resection followed by concurrent chemoradiotherapy, is an established standard of care for patients with muscle-invasive bladder cancer. For appropriately selected patients, TMT offers oncologic outcomes comparable to radical cystectomy while preserving the patient's native bladder. Optimal TMT outcomes require careful patient selection, which is currently based on clinical and pathologic factors. The role of immune checkpoint blockade (ICB) in TMT is currently being investigated in several on-going clinical trials. In the future, molecular features associated with response to TMT or ICB may further improve patient selection and guide post-treatment surveillance.

• Publication year

  2021

• Venue

  Hematology/Oncology Clinics of North America

• Publication date

  2021-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.hoc.2021.02.006PMID 33958151
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Radiotherapy With or Without Chemotherapy in Muscle-Invasive Bladder Cancer

  2021cited by this paper
• Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.

  2020cited by this paper
• Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer.

  2020cited by this paper
• Pathogenic ATM Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy.

  2020cited by this paper
• Predicting the pathologic complete response after neoadjuvant pembrolizumab in muscle-invasive bladder cancer.

  2020cited by this paper
• Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.

  2020cited by this paper
• Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.

  2019cited by this paper
• MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder Cancer

  2019cited by this paper
• Long-term outcomes of hypoxia modification in bladder preservation: Update from BCON trial.

  2019cited by this paper
• A Consensus Molecular Classification of Muscle-invasive Bladder Cancer

  2019cited by this paper
• Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma.

  2019cited by this paper
• Combining Immunotherapy with Radiotherapy for the Treatment of Genitourinary Malignancies.

  2019cited by this paper
• Integrated Gene Expression Score in Circulating Tumor Cells to Predict Treatment Response in Muscle-Invasive Bladder Cancer

  2019cited by this paper
• Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial

  2019cited by this paper
• Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial.

  2019cited by this paper
• Cancer Susceptibility Mutations in Patients With Urothelial Malignancies.

  2019cited by this paper
• Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC

  2019cited by this paper
• Safety of combining radiotherapy with immune-checkpoint inhibition

  2018cited by this paper
• Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

  2018cited by this paper
• Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study.

  2018cited by this paper
• Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers.

  2018cited by this paper
• Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.

  2018cited by this paper
• Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy

  2018cited by this paper
• Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms

  2018cited by this paper
• A Convergence-Based Framework for Cancer Drug Resistance.

  2018cited by this paper
• DNA Damage Response Gene Alterations in Urothelial Cancer: Ready for Practice?

  2018cited by this paper
• Comparative Effectiveness of Bladder‐preserving Tri‐modality Therapy Versus Radical Cystectomy for Muscle‐invasive Bladder Cancer

  2018cited by this paper
• Radiotherapy induces responses of lung cancer to CTLA-4 blockade

  2018cited by this paper
• Dose-limiting Urinary Toxicity With Pembrolizumab Combined With Weekly Hypofractionated Radiation Therapy in Bladder Cancer.

  2018cited by this paper
• DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma

  2017cited by this paper
• A Gene Signature for Selecting Benefit from Hypoxia Modification of Radiotherapy for High-Risk Bladder Cancer Patients

  2017cited by this paper
• Clinical Outcomes of Patients with Histologic Variants of Urothelial Cancer Treated with Trimodality Bladder-sparing Therapy.

  2017cited by this paper
• DNA Damage and Repair Biomarkers of Immunotherapy Response.

  2017cited by this paper
• Treatment of Non‐Metastatic Muscle‐Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline

  2017cited by this paper
• The Impact of MRE11 in Nuclear to Cytoplasmic Ratio on Outcomes in Muscle Invasive Bladder Cancer: an Analysis of NRG/RTOG 8802, 8903, 9506, 9706, 9906, and 0233.

  2017cited by this paper
• A Phase 1/2 Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation After Transurethral Surgery for Noncystectomy Candidates With Muscle-Invasive Bladder Cancer (Trial NRG Oncology RTOG 0524).

  2017cited by this paper
• Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.

  2017cited by this paper
• Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.

  2017cited by this paper
• Radical Cystectomy Compared to Combined Modality Treatment for Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.

  2017cited by this paper
• Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.

  2017cited by this paper
• Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.

  2017cited by this paper
• The prognostic and diagnostic value of circulating tumor cells in bladder cancer and upper tract urothelial carcinoma: a meta-analysis of 30 published studies

  2017cited by this paper
• Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma.

  2016cited by this paper
• Somatic ERCC2 Mutations Are Associated with a Distinct Genomic Signature in Urothelial Tumors

  2016cited by this paper
• Genomic characterization of response to chemoradiation in urothelial bladder cancer

  2016cited by this paper
• Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

  2016cited by this paper
• Immunotherapy and Radiation – A New Combined Treatment Approach for Bladder Cancer?

  2015cited by this paper
• Clinical features and outcomes of nontransitional cell carcinomas of the urinary bladder: Analysis of 125 cases

  2015cited by this paper
• Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy.

  2015cited by this paper
• Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.

  2015cited by this paper
• Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer.

  2015cited by this paper
• Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer

  2015cited by this paper
• Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma.

  2014cited by this paper
• Stereotactic Radiation Therapy Augments Antigen-Specific PD-1–Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen

  2014cited by this paper
• Long-term outcomes among patients who achieve complete or near-complete responses after the induction phase of bladder-preserving combined modality therapy for muscle-invasive bladder cancer: A pooled analysis of RTOG 9906 and 0233.

  2014cited by this paper
• Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.

  2014cited by this paper
• Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233.

  2014cited by this paper
• Randomized Noninferiority Trial of Reduced High-Dose Volume Versus Standard Volume Radiation Therapy for Muscle-Invasive Bladder Cancer: Results of the BC2001 Trial (CRUK/01/004)

  2013cited by this paper
• Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial.

  2013cited by this paper
• Expression of TIP60 (tat‐interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment‐specific outcome of localised invasive bladder cancer

  2012cited by this paper
• Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer.

  2012cited by this paper
• Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study.

  2012cited by this paper
• Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer.

  2011cited by this paper
• International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial.

  2011cited by this paper
• Bladder cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2011cited by this paper
• LIFE AND DEATH OF SPARE (SELECTIVE BLADDER PRESERVATION AGAINST RADICAL EXCISION): REFLECTIONS ON WHY THE SPARE TRIAL CLOSED

  2010cited by this paper
• Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma.

  2010cited by this paper
• MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer.

  2010cited by this paper
• Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy.

  2009cited by this paper
• Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06.

  2009cited by this paper
• Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy.

  2009cited by this paper
• Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer.

  2008cited by this paper
• Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: results of a phase I trial.

  2004cited by this paper
• Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results.

  2002cited by this paper
• Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03.

  1999cited by this paper
• Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of radiation therapy oncology group 89-03.

  1998cited by this paper
• Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group.

  1996cited by this paper
• Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802.

  1996cited by this paper
• Effect of host immune capability on radiocurability and subsequent transplantability of a murine fibrosarcoma.

  1979cited by this paper

• A novel prognostic model based on epithelial cell progression genes identifies OAS1 as a suppressor of bladder cancer aggressiveness

  2026cites this paper
• Correlations between metformin and prognosis and adverse reactions in patients undergoing radical cystectomy followed by adjuvant GC chemotherapy for bladder cancer.

  2026cites this paper
• A multi-modal approach for decision making in bladder cancer.

  2026cites this paper
• Prognostic and predictive role of circulating tumor DNA detection in patients with muscle invasive bladder cancer: a systematic review and meta-analysis

  2025cites this paper
• Clinical outcomes of modified partial cystectomy in muscle-invasive bladder cancer: balancing tumor control and quality of life

  2025cites this paper
• Clinical and Pathological Predictors for Occult Lymph Node Involvement in Patients With Clinical Node-Negative Bladder Cancer Undergoing Radical Cystectomy.

  2025cites this paper
• Decreased Expression Levels Of PIWIL2, PIWIL3 and PIWIL4 Are Associated with Poor Prognosis and Worse Survival in Bladder Cancer Patients

  2025cites this paper
• Clinical Predictors and Prognostic Significance of Pathologic Disease Upstaging at Radical Cystectomy in Patients with Muscle-Invasive Bladder Cancer

  2025cites this paper
• Advances in diagnosis and treatment of bladder cancer

  2024cites this paper
• The next chapter in immunotherapy and radiation combination therapy - cancer-specific perspectives.

  2024cites this paper
• Activity of Enfortumab Vedotin and Sacituzumab Govitecan with Radiation in Preclinical Models of Bladder Cancer.

  2024cites this paper
• An ensemble learning model for predicting cancer-specific survival of muscle-invasive bladder cancer patients undergoing bladder preservation therapy

  2024cites this paper
• The Many Faces of Muscle-Invasive Bladder Cancer: Histopathological and Molecular Characterization.

  2023cites this paper
• ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer

  2023cites this paper
• Approaches to Clinical Complete Response after Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: Possibilities and Limitations

  2023cites this paper